News

Symrise invests in innovative enzymatic technology with sugar alternative experts Bonumose

Symrise AG has signed a minority investment agreement with Bonumose. The early-stage food ingredient manufacturer specializes in the affordable production of delicious, good-for-you rare monosaccharides (alternatives to sucrose) such as tagatose and allulose. With this strategic transaction, Symrise will accelerate growth in its sugar reduction initiatives. The area represents a high-priority focus for the North America region within the Taste, Nutrition & Health segment.

“This exciting investment forges a strategic partnership. It will enhance our flavor and taste balancing technologies with Bonumose’s innovative and economical tagatose and other alternative sweetening solutions. Combining our technologies, will enable us to offer our customers new pathways to sugar reduction and taste balancing solutions. In turn, this will allow them to reduce sugar while optimizing the taste of better-for-you products for their consumers. This applies especially in the beverage and ice-cream categories. Health forms a growing focus category for Symrise. With the support of Bonumose’s enzymatic expertise, we can bring novel and disrupting ingredients to the marketplace together”, said Nick Russell, Senior Vice President – Business Incubation Group, Symrise AG.

Bonumose opened a new R&D facility and manufacturing plant earlier this year. The facility allows for quality, consistent, and economic production of their growing portfolio of sugar alternatives. Bonumose was founded in 2016 as a start-up. It continues to grow thanks to their patented enzymatic technology. This allows for the sustainable bulk production of healthy ingredients from globally-abundant plant material.

Ed Rogers, Bonumose Chief Executive Officer and Co-Founder, said: “We feel enthusiastic about the future and the growth that the investment and partnership with Symrise enables. Now, we are coupling our expertise in tagatose and other naturally-occurring sugar alternatives with the extensive Symrise flavor proficiency and expansive portfolio across multiple platforms in both human food and animal nutrition. This creates the opportunity to offer unique value to customers. The strength of Symrise as an augmented flavor house paired with Bonumose’s patented enzymatic technology will enable cutting edge solutions to sugar reduction.”

Recent News

11/21/2024

TearSolutions, Inc. Secures $3M Series B Funding

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages. “This round of financing is significant for several reasons,

11/21/2024

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served

11/13/2024

VIPC Awards Regional Innovation Ecosystem Grant to Verge to Accelerate the Growing Innovation Economy Throughout Roanoke and The New River Valley

The Virginia Innovation Partnership Corporation (VIPC) announced that Roanoke and Blacksburg, Virginia-based Verge has been awarded a Regional Innovation Fund (RIF) grant for $200,000. Verge is the region’s front door for innovators, founders, and funders to work together and to provide a growing roster of companies – both startups and established – with resources to